U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Meta Expands AI Training With Employee Activity Tracking Tools 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DUBLIN, Ireland, Feb. 29, 2016 -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9 at 10:40AM ET.
Dr. Heffernan will provide an overview of Nexvet’s pioneering developments in the field of biopharmaceuticals for companion animals in the therapeutic areas of pain, inflammation, allergy and immuno-oncology.
A live webcast of the presentation can be accessed by visiting the investor relations section of Nexvet’s website at http://ir.nexvet.com. A replay of the webcast will be available for 30 days following the presentation.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (“mAbs”) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and has acquired biomanufacturing capabilities in Ireland.
Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected] Media Jessica Burns Berry & Company Public Relations +1 212-253-8881 [email protected]
